{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:24:05Z","timestamp":1771064645757,"version":"3.50.1"},"reference-count":96,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.annonc.2021.10.014","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T13:30:09Z","timestamp":1635427809000},"page":"158-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Seroconversion rate after vaccination against COVID-19 in patients with cancer\u2014a systematic review"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0359-0267","authenticated-orcid":false,"given":"C.","family":"Corti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-3665","authenticated-orcid":false,"given":"G.","family":"Antonarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-7208","authenticated-orcid":false,"given":"F.","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3921-2479","authenticated-orcid":false,"given":"J.P.","family":"Spano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-8002","authenticated-orcid":false,"given":"J.","family":"Barri\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3331","authenticated-orcid":false,"given":"J.M.","family":"Michot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-8357","authenticated-orcid":false,"given":"F.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.annonc.2021.10.014_bib2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"issue":"10285","key":"10.1016\/j.annonc.2021.10.014_bib3","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.10.014_bib4","article-title":"Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial","author":"Marconi","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.annonc.2021.10.014_bib5","first-page":"497","article-title":"Repurposed antiviral drugs for covid-19 \u2013 interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10241","key":"10.1016\/j.annonc.2021.10.014_bib6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"issue":"7821","key":"10.1016\/j.annonc.2021.10.014_bib7","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2021.10.014_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejca.2020.08.017","article-title":"High mortality among hospital-acquired COVID-19 infection in patients with cancer: a multicentre observational cohort study","volume":"139","author":"Elkrief","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.10.014_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2020.09.035","article-title":"Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19)","volume":"141","author":"Li\u00e8vre","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.10.014_bib10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2020.09.027","article-title":"Dutch Oncology COVID-19 consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study","volume":"141","author":"de Joode","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.10.014_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","article-title":"Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies","volume":"139","author":"Saini","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.10.014_bib12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2020.09.028","article-title":"A\u00a0systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19","volume":"141","author":"Yeked\u00fcz","year":"2020","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2021.10.014_bib13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.10.014_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2020.12.019","article-title":"Commentary: SARS-CoV-2 vaccines and cancer patients","volume":"32","author":"Corti","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.10.014_bib15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ejca.2021.01.046","article-title":"SARS-CoV-2 vaccines for cancer patients: a call to action","volume":"148","author":"Corti","year":"2021","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1016\/j.annonc.2021.10.014_bib16","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.2217\/fon-2021-0597","article-title":"Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy","volume":"17","author":"Karacin","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.annonc.2021.10.014_bib17","doi-asserted-by":"crossref","first-page":"E408","DOI":"10.1002\/ajh.26305","article-title":"Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib","volume":"96","author":"Guglielmelli","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.annonc.2021.10.014_bib18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-021-01099-x","article-title":"Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors","volume":"14","author":"Terpos","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.10.014_bib19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.annonc.2021.04.019","article-title":"Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors","volume":"32","author":"Barri\u00e8re","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.10.014_bib20","first-page":"999","article-title":"Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms","volume":"194","author":"Harrington","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.annonc.2021.10.014_bib21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"issue":"34","key":"10.1016\/j.annonc.2021.10.014_bib22","doi-asserted-by":"crossref","first-page":"eabg4081","DOI":"10.1126\/sciadv.abg4081","article-title":"Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection","volume":"7","author":"Yatim","year":"2021","journal-title":"Sci Adv"},{"issue":"8","key":"10.1016\/j.annonc.2021.10.014_bib23","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.annonc.2021.10.014_bib24","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.10.014_bib25","doi-asserted-by":"crossref","first-page":"S1129","DOI":"10.1016\/j.annonc.2021.08.1550","article-title":"1557O - Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: the CAPTURE study","volume":"32","author":"Shepherd","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2021.10.014_bib26","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2021.2675","article-title":"Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer","volume":"7","author":"Goshen-Lago","year":"2021","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.10.014_bib27","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.annonc.2021.04.020","article-title":"Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients","volume":"32","author":"Palich","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.10.014_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01354-7","article-title":"Response to mRNA vaccination for COVID-19 among patients with multiple myeloma","author":"Stampfer","year":"2021","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.annonc.2021.10.014_bib29","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.annonc.2021.10.014_bib30","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.3390\/cancers13153800","article-title":"Post-vaccination anti-SARS-CoV-2-antibody response in patients with multiple myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment","volume":"13","author":"Ghandili","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2021.10.014_bib31","article-title":"COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma","author":"Ramasamy","year":"2021","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.annonc.2021.10.014_bib32","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2021.10.014_bib33","first-page":"1","article-title":"Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies","author":"Re","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.annonc.2021.10.014_bib34","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/bjh.17644","article-title":"Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms","volume":"194","author":"Chowdhury","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.annonc.2021.10.014_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2021.10.014_bib36","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma","volume":"5","author":"Perry","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.annonc.2021.10.014_bib37","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2352-3026(21)00199-X","article-title":"Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma","volume":"8","author":"Lim","year":"2021","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.annonc.2021.10.014_bib38","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.10.014_bib39","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia","author":"Benjamini","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.annonc.2021.10.014_bib40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"Parry","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.annonc.2021.10.014_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4390","article-title":"Durability of response to SARS-CoV-2 BNT162b2 vaccination in patients on active anticancer treatment","author":"Eliakim-Raz","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2021.10.014_bib42","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.annonc.2021.06.018","article-title":"High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers","volume":"32","author":"Palich","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.10.014_bib43","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01240-w","article-title":"COVID-19 vaccination: the VOICE for patients with cancer","volume":"27","author":"van der Veldt","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.annonc.2021.10.014_bib44","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.annonc.2021.07.012","article-title":"Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients","volume":"32","author":"Heudel","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.10.014_bib45","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.10.014_bib46","article-title":"Immune responses to COVID-19 mRNA vaccines in patients with solid tumors on active, immunosuppressive cancer therapy","author":"Shroff","year":"2021","journal-title":"MedRxiv"},{"issue":"8","key":"10.1016\/j.annonc.2021.10.014_bib47","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ccell.2021.07.016","article-title":"Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer","volume":"39","author":"Ehmsen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2021.10.014_bib48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2021.06.008","article-title":"Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer","volume":"154","author":"Barri\u00e8re","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.10.014_bib49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B\u00a0cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.annonc.2021.10.014_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17743","article-title":"Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients","author":"Benda","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2021.10.014_bib51","article-title":"Brief communication: humoral and cellular responses after a third dose of BNT162b2 vaccine in patients with lymphoid malignancies","author":"Re","year":"2021","journal-title":"Research Square \u2013 Nature Portfolio"},{"issue":"10","key":"10.1016\/j.annonc.2021.10.014_bib52","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annonc.2021.10.014_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fcell.2019.00023","article-title":"Immunomodulatory roles of cell cycle regulators","volume":"7","author":"Laphanuwat","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.annonc.2021.10.014_bib54","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.breast.2021.08.017","article-title":"SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4\/6 inhibitors","volume":"60","author":"Zagouri","year":"2021","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.annonc.2021.10.014_bib55","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/COC.0000000000000788","article-title":"Vaccination and immune checkpoint inhibitors: does vaccination increase the risk of immune-related adverse events? A systematic review of literature","volume":"44","author":"Desage","year":"2021","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.10.014_bib56","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","article-title":"Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors","volume":"22","author":"Waissengrin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.10.014_bib57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.annonc.2021.10.014_bib58","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ccell.2021.08.001","article-title":"Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer","volume":"39","author":"Mairhofer","year":"2021","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.annonc.2021.10.014_bib59","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.annonc.2021.10.014_bib60","doi-asserted-by":"crossref","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"issue":"6529","key":"10.1016\/j.annonc.2021.10.014_bib61","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 accessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.annonc.2021.10.014_bib62","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41591-021-01432-4","article-title":"A\u00a0correlate of protection for SARS-CoV-2 vaccines is urgently needed","volume":"27","author":"Krammer","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2021.10.014_bib63","author":"Nanduri"},{"key":"10.1016\/j.annonc.2021.10.014_bib64","author":"Rosenberg"},{"key":"10.1016\/j.annonc.2021.10.014_bib65","author":"Tenforde"},{"key":"10.1016\/j.annonc.2021.10.014_bib66","author":"Garassino"},{"issue":"8","key":"10.1016\/j.annonc.2021.10.014_bib67","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-21-0191","article-title":"Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in patients with cancer","volume":"11","author":"Bilich","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2021.10.014_bib68","article-title":"Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses","author":"Gounant","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.annonc.2021.10.014_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.03.033","article-title":"Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients","volume":"150","author":"Mansi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10303","key":"10.1016\/j.annonc.2021.10.014_bib70","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"issue":"41","key":"10.1016\/j.annonc.2021.10.014_bib71","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1016\/j.vaccine.2012.07.028","article-title":"Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults","volume":"30","author":"Potsch","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.annonc.2021.10.014_bib72","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/bloodadvances.2020003880","article-title":"Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias","volume":"5","author":"Branagan","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.annonc.2021.10.014_bib73","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12664-015-0595-y","article-title":"The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy","volume":"34","author":"Sodhi","year":"2015","journal-title":"Indian J Gastroenterol"},{"issue":"7830","key":"10.1016\/j.annonc.2021.10.014_bib74","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.annonc.2021.10.014_bib75","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.10.014_bib76","unstructured":"GOV.UK: OCTAVE DUO \u2013 New study to test third COVID-19 vaccine for people with weakened immune systems [press release, Available at https:\/\/bit.ly\/3zTQpQm], 2021. Accessed September 2,\u00a02021."},{"key":"10.1016\/j.annonc.2021.10.014_bib77","article-title":"Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity \u2013 the OCTAVE Trial","author":"Kearns","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.10.014_bib78","article-title":"A\u00a0third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients","author":"Karaba","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.annonc.2021.10.014_bib79","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2021.10.014_bib80","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/ndt\/gfab193","article-title":"High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients","volume":"36","author":"Longlune","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.annonc.2021.10.014_bib81","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2021.10.014_bib82","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.7326\/L21-0282","article-title":"Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series","volume":"174","author":"Werbel","year":"2021","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.annonc.2021.10.014_bib83","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients","volume":"385","author":"Hall","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2021.10.014_bib84","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jama.2021.12339","article-title":"Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses","volume":"326","author":"Benotmane","year":"2021","journal-title":"J\u00a0Am Med A"},{"issue":"8","key":"10.1016\/j.annonc.2021.10.014_bib88","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ccell.2021.07.001","article-title":"Immune responses to COVID-19 vaccines in patients with cancer: promising results and a note of caution","volume":"39","author":"Griffiths","year":"2021","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.annonc.2021.10.014_bib89","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.annonc.2021.10.014_bib90","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41591-021-01435-1","article-title":"A\u00a0French cohort for assessing COVID-19 vaccine responses in specific populations","volume":"27","author":"Loubet","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.annonc.2021.10.014_bib91","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41571-021-00487-z","article-title":"COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials","volume":"18","author":"Desai","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2021.10.014_bib92","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-2439","article-title":"Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution","author":"Di Noia","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.10.014_bib93","article-title":"Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations","author":"Mair","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2021.10.014_bib94","first-page":"568","article-title":"Reasons for incomplete immunisation among Australian children. A national survey of parents","volume":"33","author":"Lawrence","year":"2004","journal-title":"Aust Fam Physician"},{"issue":"15","key":"10.1016\/j.annonc.2021.10.014_bib95","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.3390\/cancers13153883","article-title":"Cancer patients' willingness to take COVID-19 vaccination: a nationwide multicenter survey in Korea","volume":"13","author":"Chun","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.annonc.2021.10.014_bib96","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.annonc.2021.01.066","article-title":"Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey","volume":"32","author":"Barri\u00e8re","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.10.014_bib97","doi-asserted-by":"crossref","first-page":"e20190802","DOI":"10.1542\/peds.2019-0802","article-title":"Previsit screening for parental vaccine hesitancy: a cluster randomized trial","volume":"144","author":"Opel","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.annonc.2021.10.014_bib98","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejca.2021.05.007","article-title":"Adherence to COVID-19 vaccines in cancer patients: promote it and make it happen!","volume":"153","author":"Curigliano","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.10.014_bib99","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejca.2021.05.006","article-title":"The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: early data from a single-institute survey","volume":"153","author":"Di Noia","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2021.10.014_bib100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bulcan.2021.02.001","article-title":"COVID-19 vaccination for cancer patients: medical and ethical need","volume":"108","author":"Spano","year":"2021","journal-title":"Bull Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421045506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421045506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:07:23Z","timestamp":1760335643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421045506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0923753421045506"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.10.014","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seroconversion rate after vaccination against COVID-19 in patients with cancer\u2014a systematic review","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}